QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 theriva-biologics-announces-that-the-thericel-project-has-been-awarded-funding-of-228-million-from-the-national-knowledge-transfer-program-of-the-spanish-governments-ministry-of-science-innovation--universities-to-support-a-collaboration-between-the-universitat-autnoma-de-barcelona-to-advance-the-companys-suspension-cell-platform-for-the-clinical-manufacture-of-adenovirus--and-adeno-associated-virus-therapies

Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company") a diversified clinical-stage company developing th...

 whats-going-on-with-theriva-biologics-stock

Theriva Biologics shares are trading higher Friday on continued momentum following a series of catalysts this week. Here's ...

 whats-going-on-with-theriva-biologics-tovx-stock

Theriva Biologics shares are trading lower by 8.4% Monday morning. The company announced a 1-for-25 reverse stock split.

 theriva-biologics-announces-1-for-25-reverse-stock-split-effective-august-26-2024

Theriva Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in...

 theriva-biologics-q2-eps-043-misses-019-estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION